Sanofi paying big for FDA voucher; Retrophin snags $245m

It didn't take Retrophin long to find a buyer for the FDA priority review voucher it snapped up in March when it exercised its rights to purchase the newly approved Cholbam (cholic acid) from Asklepion Pharmaceuticals for $27m plus 661,278 shares of the former firm's common stock.